Literature DB >> 28600294

Cervical intraepithelial neoplasia (CIN) in African women living with HIV: role and effect of rigorous histopathological review by a panel of pathologists in the HARP study endpoint determination.

Sylviane Doutre1, Tanvier Omar2, Olga Goumbri-Lompo3, Helen Kelly4, Omar Clavero5, Souleymane Zan6, Admire Chikandiwa7, Bernard Sawadogo8, Sinead Delany-Moretlwe7, Valérie Costes1,9, Philippe Mayaud4,7, Michel Segondy1,9.   

Abstract

AIMS: To analyse the effect of the expert end-point committee (EPC) review on histological endpoint classification of cervical intraepithelial neoplasia (CIN).
METHODS: A cohort of women living with HIV were recruited in Burkina Faso (BF) and South Africa (SA) and followed over 18 months. Four-quadrant cervical biopsies were obtained in women with abnormalities detected by at least one screening test. A central review by a panel of five pathologists was organised at baseline and at endline.
RESULTS: At baseline the prevalence of high-grade CIN (CIN2+) was 5.1% (28/554) in BF and 23.3% (134/574) in SA by local diagnosis, and 5.8% (32/554) in BF and 22.5% (129/574) in SA by the EPC. At endline the prevalence of CIN2+ was 2.3% (11/483) in BF and 9.4% (47/501) in SA by local diagnosis, and 1.4% (7/483) in BF and 10.2% (51/501) in SA by EPC. The prevalence of borderline CIN1/2 cases was 2.8% (32/1128) and 0.8% (8/984) at baseline and endline. Overall agreement between local diagnosis and final diagnosis for distinguishing CIN2+ from ≤CIN1 was 91.2% (κ=0.82) and 88.9% (κ=0.71) for BF at baseline and endline, and 92.7% (κ=0.79) and 98.7% (κ=0.97) for SA at baseline and endline. Among the CIN1/2 cases, 12 (37.5%) were graded up to CIN2 and 20 (62.5%) were graded down to CIN1 at baseline, and 3 (37.5%) were graded up to CIN2 and 5 (62.5%) were graded down to CIN1 at endline.
CONCLUSIONS: This study highlights the importance of a centralised rigorous re-reading with exchange of experiences among pathologists from different settings. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  HIV; cervical cancer; histopathology

Mesh:

Substances:

Year:  2017        PMID: 28600294     DOI: 10.1136/jclinpath-2017-204512

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer.

Authors:  Mahdieh Farzanehpour; Sayed-Hamidreza Mozhgani; Somayeh Jalilvand; Ebrahim Faghihloo; Setareh Akhavan; Vahid Salimi; Talat Mokhtari Azad
Journal:  Virol J       Date:  2019-10-07       Impact factor: 4.099

2.  Comparison of Snail1, ZEB1, E-Cadherin Expression Levels in HPV-Induced Cervical Cancer.

Authors:  Mahdieh Farzanehpour; Ebrahim Faghihloo; Vahid Salimi; Somayeh Jalilvand; Setareh Akhavan; Ahad Muhammadnejad; Amir Nader Emami Razavi; Ehsan Kakavandi; Talat Mokhtari Azad
Journal:  Iran J Public Health       Date:  2020-11       Impact factor: 1.429

3.  Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.

Authors:  Angela Devine; Alice Vahanian; Bernard Sawadogo; Souleymane Zan; Fadima Yaya Bocoum; Helen Kelly; Clare Gilham; Nicolas Nagot; Jason J Ong; Rosa Legood; Nicolas Meda; Alec Miners; Philippe Mayaud
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

4.  Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.

Authors:  Helen A Kelly; Admire Chikandiwa; Bernard Sawadogo; Clare Gilham; Pamela Michelow; Olga Goumbri Lompo; Tanvier Omar; Souleymane Zan; Precious Magooa; Michel Segondy; Nicolas Nagot; Nicolas Meda; Sinead Delany-Moretlwe; Philippe Mayaud
Journal:  PLoS Med       Date:  2021-03-04       Impact factor: 11.069

5.  P16INK4A Immunohistochemistry as a Gold Standard for Cervical Cancer and Precursor Lesions Screening.

Authors:  Mahdieh Farzanehpour; Ahad Muhammadnejad; Setareh Akhavan; Amir Nader Emami Razavi; Somayeh Jalilvand; Vahid Salimi; Ebrahim Faghihloo; Ehsan Kakavandi; Mohammad Farahmand; Mohammad Shayestehpour; Farzad Babakhani; Talat Mokhtari Azad
Journal:  Iran J Public Health       Date:  2020-02       Impact factor: 1.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.